Maintenance regimens after a second autologous transplant for multiple myeloma
Leuk Lymphoma
.
2021 Mar;62(3):758-760.
doi: 10.1080/10428194.2020.1842402.
Epub 2020 Nov 4.
Authors
Ghulam Rehman Mohyuddin
1
,
Maire Okoniewski
2
,
Osama Diab
3
,
Siddhartha Ganguly
4
,
Leyla Shune
4
,
Al-Ola Abdallah
4
,
Joseph McGuirk
4
,
Brian McClune
5
Affiliations
1
Division of Hematology-Oncology, University of Kansas Cancer Center, Westwood, KS, USA.
2
Department of Internal Medicine, University of Kansas, Kansas City, KS, USA.
3
Division of Hematology Oncology, University of Kansas, Kansas City, KS, USA.
4
Department of Hematological Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, KS, USA.
5
Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
PMID:
33146051
DOI:
10.1080/10428194.2020.1842402
No abstract available
Publication types
Letter
MeSH terms
Autografts
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / therapy
Thalidomide
Transplantation, Autologous
Substances
Thalidomide